Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ: AVIR )

3.150 +0.040 (+1.29%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 Next >
Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases
71% reduction in risk of hospitalization for mild to moderate COVID-19 outpatients treated with bemnifosbuvir versus placebo in MORNINGSKY study, regardless of vaccination status 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Preview: Atea Pharmaceuticals's Earnings
Via Benzinga
Atea Pharma's Investigational Dengue Treatment Fast Tracked In US
Via Benzinga
Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir
Via Benzinga
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday, 79 stocks hit new 52-week lows. 
Via Benzinga
Recap: Atea Pharmaceuticals Q2 Earnings
  Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Short Volatility Alert: Atea Pharmaceuticals
On Tuesday, shares of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) experienced volatile short activity. After the activity, the stock price went down -1.73% to $7.38. The... 
Via Benzinga
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 35 stocks hit new 52-week lows. 
Via Benzinga
Atea Pharmaceuticals: Q1 Earnings Insights
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Highlights Strategic Priorities for 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Earnings Preview
Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Atea... 
Via Benzinga
Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion?
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now? 
Via Investor's Business Daily
Stocks Selling For Less Than Cash Per Share
How do you go about choosing a stock to buy in these volatile times? One strategy is to look for stocks that are not only selling below their book value, but also below their cash per share, especially... 
Via Talk Markets
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Preview For Atea Pharmaceuticals
Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Atea... 
Via Benzinga
How To Attend Atea Pharmaceuticals Q1 2022 Earnings Conference Call
Atea Pharmaceuticals (NASDAQ:AVIR) will host a conference call at 10:00 AM ET on May 10, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.